These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32439328)

  • 1. Quantitative Differentiation of Protein Aggregates From Other Subvisible Particles in Viscous Mixtures Through Holographic Characterization.
    Winters A; Cheong FC; Odete MA; Lumer J; Ruffner DB; Mishra KI; Grier DG; Philips LA
    J Pharm Sci; 2020 Aug; 109(8):2405-2412. PubMed ID: 32439328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow cytometry: a promising technique for the study of silicone oil-induced particulate formation in protein formulations.
    Ludwig DB; Trotter JT; Gabrielson JP; Carpenter JF; Randolph TW
    Anal Biochem; 2011 Mar; 410(2):191-9. PubMed ID: 21146492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Subvisible Particles in Biotherapeutic Prefilled Syringes: The Role of Polysorbate and Protein on the Formation of Silicone Oil and Protein Subvisible Particles After Drop Shock.
    Jiao N; Barnett GV; Christian TR; Narhi LO; Joh NH; Joubert MK; Cao S
    J Pharm Sci; 2020 Jan; 109(1):640-645. PubMed ID: 31689431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Incremental Siliconization Levels on Soluble Aggregates, Submicron and Subvisible Particles in a Prefilled Syringe Product.
    Bai S; Landsman P; Spencer A; DeCollibus D; Vega F; Temel DB; Houde D; Henderson O; Brader ML
    J Pharm Sci; 2016 Jan; 105(1):50-63. PubMed ID: 26852839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Backgrounded Membrane Imaging (BMI) for High-Throughput Characterization of Subvisible Particles During Biopharmaceutical Drug Product Development.
    Helbig C; Ammann G; Menzen T; Friess W; Wuchner K; Hawe A
    J Pharm Sci; 2020 Jan; 109(1):264-276. PubMed ID: 30914272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring polysorbate 80 degradation in protein solutions using Total Holographic Characterization.
    Markus T; Lumer J; Stasavage R; Ruffner DB; Philips LA; Cheong FC
    Int J Pharm; 2024 Mar; 652():123843. PubMed ID: 38266941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Holographic Characterization of Protein Aggregates.
    Wang C; Zhong X; Ruffner DB; Stutt A; Philips LA; Ward MD; Grier DG
    J Pharm Sci; 2016 Mar; 105(3):1074-85. PubMed ID: 26886303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of subvisible silicone oil droplets from irregular standard dust particles.
    Vandesteeg N; Kilbert C
    J Pharm Sci; 2013 Jun; 102(6):1696-1700. PubMed ID: 23595940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Subvisible Particle Formation in Lyophilized Intravenous Immunoglobulin Formulations Containing Polysorbate 20.
    Zhou C; Qi W; Lewis EN; Randolph TW; Carpenter JF
    J Pharm Sci; 2016 Aug; 105(8):2302-9. PubMed ID: 27290624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
    Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
    Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oil-Immersion Flow Imaging Microscopy for Quantification and Morphological Characterization of Submicron Particles in Biopharmaceuticals.
    Krause N; Kuhn S; Frotscher E; Nikels F; Hawe A; Garidel P; Menzen T
    AAPS J; 2021 Jan; 23(1):13. PubMed ID: 33398482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Holographic characterization of contaminants in water: Differentiation of suspended particles in heterogeneous dispersions.
    Philips LA; Ruffner DB; Cheong FC; Blusewicz JM; Kasimbeg P; Waisi B; McCutcheon JR; Grier DG
    Water Res; 2017 Oct; 122():431-439. PubMed ID: 28624726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator.
    Patel AR; Lau D; Liu J
    Anal Chem; 2012 Aug; 84(15):6833-40. PubMed ID: 22794526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Protein Aggregates, Silicone Oil Droplets, and Protein-Silicone Interactions Using Imaging Flow Cytometry.
    Probst C
    J Pharm Sci; 2020 Jan; 109(1):364-374. PubMed ID: 31136765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effect of syringe surfaces on protein formulations.
    Majumdar S; Ford BM; Mar KD; Sullivan VJ; Ulrich RG; D'souza AJ
    J Pharm Sci; 2011 Jul; 100(7):2563-73. PubMed ID: 21319164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling.
    Liu L; Ammar DA; Ross LA; Mandava N; Kahook MY; Carpenter JF
    Invest Ophthalmol Vis Sci; 2011 Feb; 52(2):1023-34. PubMed ID: 21051703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards quantification and differentiation of protein aggregates and silicone oil droplets in the low micrometer and submicrometer size range by using oil-immersion flow imaging microscopy and convolutional neural networks.
    Umar M; Krause N; Hawe A; Simmel F; Menzen T
    Eur J Pharm Biopharm; 2021 Dec; 169():97-102. PubMed ID: 34597817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Strengths of Total Holographic Video Microscopy in Detecting Sub-Visible Protein Particles in Biopharmaceuticals: A Comparison to Flow Imaging and Resonant Mass Measurement.
    Rahn H; Oeztuerk M; Hentze N; Junge F; Hollmann M
    J Pharm Sci; 2023 Apr; 112(4):985-990. PubMed ID: 36596393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic Investigation on Grinding-Induced Subvisible Particle Formation during Mixing and Filling of Monoclonal Antibody Formulations.
    Gikanga B; Hui A; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(2):117-133. PubMed ID: 29030532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.